Renaissance Technologies LLC Sells 312,950 Shares of OPKO Health, Inc. (NASDAQ:OPK)

Renaissance Technologies LLC cut its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 68.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 145,977 shares of the biotechnology company's stock after selling 312,950 shares during the quarter. Renaissance Technologies LLC's holdings in OPKO Health were worth $215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Tejara Capital Ltd boosted its holdings in OPKO Health by 11.3% during the 4th quarter. Tejara Capital Ltd now owns 1,225,650 shares of the biotechnology company's stock valued at $1,802,000 after acquiring an additional 124,524 shares during the period. PFG Investments LLC raised its position in OPKO Health by 9.4% during the 4th quarter. PFG Investments LLC now owns 1,160,885 shares of the biotechnology company's stock valued at $1,707,000 after purchasing an additional 99,795 shares during the last quarter. Norges Bank bought a new position in OPKO Health during the 4th quarter valued at approximately $1,657,000. Barclays PLC raised its position in OPKO Health by 154.5% during the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company's stock valued at $810,000 after purchasing an additional 329,870 shares during the last quarter. Finally, Essential Planning LLC. bought a new position in OPKO Health during the 4th quarter valued at approximately $506,000. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock in a transaction that occurred on Thursday, April 10th. The stock was bought at an average price of $1.36 per share, with a total value of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares in the company, valued at approximately $291,041,969.28. This represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders bought 767,434 shares of company stock valued at $1,238,312. Corporate insiders own 49.69% of the company's stock.

OPKO Health Stock Up 1.2%

Shares of NASDAQ:OPK traded up $0.02 during trading on Monday, hitting $1.26. The stock had a trading volume of 200,400 shares, compared to its average volume of 3,885,762. OPKO Health, Inc. has a 12 month low of $1.19 and a 12 month high of $2.04. The company has a market capitalization of $995.28 million, a PE ratio of -6.61 and a beta of 1.42. The firm's fifty day moving average is $1.57 and its 200 day moving average is $1.56. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The firm had revenue of $149.90 million during the quarter, compared to the consensus estimate of $163.13 million. During the same period in the prior year, the company posted ($0.12) EPS. The firm's revenue was down 13.7% on a year-over-year basis. Analysts anticipate that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research report on Friday, April 25th. They set a "neutral" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. StockNews.com lowered OPKO Health from a "hold" rating to a "sell" rating in a research report on Monday, May 5th. Finally, Barrington Research reaffirmed an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat, OPKO Health currently has a consensus rating of "Hold" and a consensus price target of $2.75.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.